These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 25302109)
1. Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence. Riverol M; Slachevsky A; López OL Eur Neurol J; 2011 Jul; 3(1):15-19. PubMed ID: 25302109 [TBL] [Abstract][Full Text] [Related]
2. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis. Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879 [TBL] [Abstract][Full Text] [Related]
3. Treatment of Alzheimer's disease in the long-term-care setting. Smith DA Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308 [TBL] [Abstract][Full Text] [Related]
4. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Atri A; Molinuevo JL; Lemming O; Wirth Y; Pulte I; Wilkinson D Alzheimers Res Ther; 2013; 5(1):6. PubMed ID: 23336974 [TBL] [Abstract][Full Text] [Related]
5. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease. Deardorff WJ; Grossberg GT Drug Des Devel Ther; 2016; 10():3267-3279. PubMed ID: 27757016 [TBL] [Abstract][Full Text] [Related]
6. Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies. Forchetti CM Prim Care Companion J Clin Psychiatry; 2005; 7(4):155-61. PubMed ID: 16163398 [TBL] [Abstract][Full Text] [Related]
7. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366 [TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339 [TBL] [Abstract][Full Text] [Related]
9. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Gauthier S; Molinuevo JL Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864 [TBL] [Abstract][Full Text] [Related]
10. An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease. Calhoun A; King C; Khoury R; Grossberg GT Expert Opin Pharmacother; 2018 Oct; 19(15):1711-1717. PubMed ID: 30244611 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials. Molino I; Colucci L; Fasanaro AM; Traini E; Amenta F ScientificWorldJournal; 2013; 2013():925702. PubMed ID: 24288512 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). Knapp M; King D; Romeo R; Adams J; Baldwin A; Ballard C; Banerjee S; Barber R; Bentham P; Brown RG; Burns A; Dening T; Findlay D; Holmes C; Johnson T; Jones R; Katona C; Lindesay J; Macharouthu A; McKeith I; McShane R; O'Brien JT; Phillips PPJ; Sheehan B; Howard R Int J Geriatr Psychiatry; 2017 Dec; 32(12):1205-1216. PubMed ID: 27739182 [TBL] [Abstract][Full Text] [Related]
14. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Thompson S; Lanctôt KL; Herrmann N Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298 [TBL] [Abstract][Full Text] [Related]
15. Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. Kishi T; Matsunaga S; Oya K; Nomura I; Ikuta T; Iwata N J Alzheimers Dis; 2017; 60(2):401-425. PubMed ID: 28922160 [TBL] [Abstract][Full Text] [Related]
16. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials. Dou KX; Tan MS; Tan CC; Cao XP; Hou XH; Guo QH; Tan L; Mok V; Yu JT Alzheimers Res Ther; 2018 Dec; 10(1):126. PubMed ID: 30591071 [TBL] [Abstract][Full Text] [Related]
17. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Beier MT Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151 [TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Standridge JB Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008 [TBL] [Abstract][Full Text] [Related]
19. Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis. Guo J; Wang Z; Liu R; Huang Y; Zhang N; Zhang R Brain Behav; 2020 Nov; 10(11):e01831. PubMed ID: 32914577 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]